Clinical Trials Directory

Trials / Unknown

UnknownNCT03876197

Mesenchymal Stem Cells for Radiation-induced Xerostomia

Follow-up Study of Safety and Efficacy in Subjects Who Participated in the Study of Intraglandular Mesenchymal Stem Cells in Patients With Radiation-induced Hyposalivation and Xerostomia (MESRIX)

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Rigshospitalet, Denmark · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

A prospective study for long-term follow-up (LTFU) to evaluate safety and efficacy in subjects who participated in the Phase 1/2 randomized placebo-controlled trial MESRIX.

Detailed description

This is a LTFU study to assess the long-term and late effects of treatment with MSCs or placebo given ultrasound-guided into the submandibular glands in subjects participating in the MESRIX trial. Study participants from the MESRIX trial will be invited for a clinical visit. The visit will include medical history, an ENT examination; measurements of the saliva production by sialometry, a Magnetic resonance imaging scan (MRI) and obtaining data on the patient-reported outcome with Xerostomia Questionnaire (XQ) and Visual-Analogue-Symptomatic scale (VAS). Subjects, who are not able or willing to attend a clinical visit, will be encouraged to fill out the Questionnaires online or on paper. If a study participant has deceased, information of the cause of death will be investigated in The Danish Register of Causes of Death

Conditions

Interventions

TypeNameDescription
BIOLOGICALAutologous adipose-derived mesenchymal stem/stromal cellsAutologous adipose-derived mesenchymal stem/stromal cells
OTHERPlaceboIsotonic NaCl (0,9mg/ml) and human albumin (HA) 1%

Timeline

Start date
2020-08-01
Primary completion
2022-12-01
Completion
2023-12-01
First posted
2019-03-15
Last updated
2020-10-22

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT03876197. Inclusion in this directory is not an endorsement.